These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21168618)

  • 21. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Early steroid withdrawal in pediatric renal transplantation].
    Delucchi B A; Valenzuela A M; Ferrario B M; Lillo D AM; Guerrero G JL; Rodríguez S E; Cano Sch F; Cavada Ch G; Godoy L J; Rodríguez H J; González G G; Buckel B E; Contreras M L
    Rev Med Chil; 2006 Nov; 134(11):1393-401. PubMed ID: 17277852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
    Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
    Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.
    Rajab A; Pelletier RP; Henry ML; Ferguson RM
    Clin Transplant; 2006; 20(5):537-46. PubMed ID: 16968478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.
    Yoshimura N; Ushigome H; Akioka K; Nobori S; Suzuki T; Sakai K; Okamoto M
    Clin Exp Nephrol; 2013 Feb; 17(1):127-33. PubMed ID: 23011290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rejection is a strong graft survival predictor in live donor pediatric renal transplantation using cyclosporine, mycophenolate mofetil, and steroids: 5-year outcomes in a single Mexican center.
    Martinez-Mier G; Enriquez-De Los Santos H; Méndez-López MT; Avila-Pardo SF; Budar-Fernandez LF; Gonzalez-Velazquez F
    Transplant Proc; 2013 May; 45(4):1442-4. PubMed ID: 23726592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
    Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
    Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation.
    De Paolis P; Favarò A; Piola A; Martini F; Cristiana G; Agrati C; Iappelli M; Di Giulio S
    Transplant Proc; 2011 May; 43(4):1013-6. PubMed ID: 21620039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tacrolimus combined with two different corticosteroid-free regimens compared with a standard triple regimen in renal transplantation: one year observational results.
    Krämer BK; Klinger M; Wlodarczyk Z; Ostrowski M; Midvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Vítko S; Senatorski G; Salmela K; Nordström J
    Clin Transplant; 2010; 24(1):E1-9. PubMed ID: 19925464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.